Apomorphine and piribedil in rats: biochemical and pharmacologic studies.
We studied the biochemical and pharmacologic modes of action of piribedil and apomorphine in the rat. Although both drugs have many points in common, they are also different in many of their manifestations. Apomorphine causes high-intensity, short-duration stereotyped behavior; it is distributed within the brain in uneven fashion, the striatum being the area of lowest concentration as measured by fluorometry. Direct stereotactic injection within the dopaminergic mesolimbic system, and particularly the tuberculum olfactorium, produced constant intense responses. All effects of apomorphine can be blocked by pimozide, but propanolol, a beta blocker, only reduces aggression and ferocity, leaving stereotyped behaviors intact. Finally, L-5-HTP tends to reduce aggression, ferocity, and to a lesser extent stereotypy; MIF or piribedil, as well as reserpine, potentiates the stereotyped behaviors induced by apomorphine, whereas L-DOPA usually decreases them. Piribedil, on the other hand, causes low-intensity, long-duration stereotyped behavior. It is distributed within the brain almost uniformly. Most effects of piribedil can be blocked by pimozide, but propanolol blocks only aggression and ferocity, leaving stereotyped behaviors intact. On the other hand, clonidine, an alpha-receptor agonist, blocks stereotyped behaviors induced by piribedil but markedly increases aggression, ferocity, and motor activity. L-5-HTP and L-DOPA have little effect on piribedil-induced manifestations. Reserpine decreases piribedil stereotypy. The main metabolite of piribedil, S 584, had no clear-cut pharmacologic action in our hands at the dosage used. It is concluded that both apomorphine and piribedil produce stereotyped behavior by modifying the physiologic balance between mesolimbic and nigrostriatal dopaminergic systems. The other actions of apomorphine and piribedil upon aggression, ferocity, and motor activity are not always in parallel and depend probably on the fact that piribedil is less specific, affecting also noradrenergic, serotonergic, histaminergic, and/or cholinergic circuits. The usefulness of piribedil against some forms of human tremor and its low-intensity antiakinetic action probably result from this pattern of pharmacologic activity.
D000679:Amygdala / Q000187:drug effects; D000818:Animals; D001058:Apomorphine / Q000378:metabolism / Q000494:pharmacology*; D001519:Behavior / Q000187:drug effects*; D001921:Brain / Q000378:metabolism; D003342:Corpus Striatum / Q000187:drug effects; D004357:Drug Synergism; D006624:Hippocampus / Q000187:drug effects; D006801:Humans; D007031:Hypothalamus / Q000187:drug effects; D009069:Movement Disorders / Q000139:chemically induced* / Q000188:drug therapy; D009830:Olfactory Bulb / Q000187:drug effects; D010879:Piperazines / Q000494:pharmacology*; D010891:Piribedil / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D011955:Receptors, Drug; D012110:Reserpine / Q000627:therapeutic use; D013239:Stereotyped Behavior / Q000187:drug effects*
D010879:Piperazines; D011955:Receptors, Drug; D012110:Reserpine; D010891:Piribedil; D001058:Apomorphine